Capitol Hill In Brief
This article was originally published in The Gray Sheet
Executive Summary
Import safety bill: A new draft of the drug portion of the proposed FDA Globalization Act crafted by the House Energy and Commerce Committee and posted on the panel's website July 28 indicates that Congress is continuing its work on the measure, but in separate pieces. The only language pertaining to devices in the draft is the requirement that each drug and device establishment have a unique identification number. However, the House panel is still interested in addressing imported medical device safety, and will most likely take up that section of the bill after the congressional recess ends on Sept. 8, a house staffer said. At a hearing on the act in May, Republican members of the committee's Health Subcommittee, including Rep. Joe Barton of Texas, supported an industry position on the bill that the device components of it should be removed and dealt with separately. Barton opposed requirements in the legislation calling for pre-market inspections of all class II 510(k) devices ("1The Gray Sheet" May 19, 2008, p. 4)
You may also be interested in...
Industry Opposes Idea Of New FDA Inspection Authority, Fee At House Hearing
Several device industry representatives told lawmakers on Capitol Hill May 14 that additional FDA user fees and expansion of pre-approval inspection authority to include less risky, Class II devices should not be part of a proposed bill making its way through Congress. They got support from the Republican members of the panel
Democrats Seek To Overturn Supreme Court Device Liability Decision
Democratic leaders in Congress are vowing to craft legislation to effectively overturn the Supreme Court's ruling that PMA approval pre-empts a patient's right to sue device companies for personal injury
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.